Stephen A. Black

Stephen A. Black

Auto-generated profile, based on publicly available information

Stephen A. Black

St Thomas' Hospital, King's College London, London, UK

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Open access
PDF file
EMErin Murphy
Erin Murphy
KGKathleen Gibson
Kathleen Gibson
MSMarc Sapoval
Marc Sapoval
DDDavid J. Dexter
David J. Dexter
RKRaghu Kolluri
Raghu Kolluri
SBStephen Black
Stephen Black
Background: Iliofemoral venous obstruction is recognized with increasing frequency as the underlying cause of lower extremity symptoms including edema, pain, skin changes, and, in advanced cases, ulceration. This study sought to evaluate the safety and effectiveness of the Abre venous self-expanding stent system for the treatment of symptomatic iliofemoral venous outflow obstruction. Methods: The ABRE Study (A Multi-Center, Non-Randomized Study to Evaluate the Safety and Effectiveness of the Abre Venous Self-Expanding Stent System in Patients With Symptomatic Iliofemoral Venous Outflow Obstruction) is a single-arm, multicenter, prospective study that included 200 subjects from 24 global sites. The primary end points were 12-month primary patency and major adverse events within 30 days. Secondary end points included lesion and procedure success, primary-assisted and secondary patency, major adverse events, stent migration, stent fracture, and quality of life changes. End point-related adverse events and imaging studies were adjudicated by independent clinical events committee and core laboratories, respectively. Results: Venous obstruction cause was classified as acute deep vein thrombosis (16.5%, 33/200), post-thrombotic syndrome (47.5%, 95/200), or nonthrombotic iliac vein lesion (36.0%, 72/200). The common iliac and external iliac veins were stented in 96.0% (192/200), 80.5% (161/200) of subjects, respectively. Stent implant into the common femoral vein was required in 44.0% (88/200). Primary patency at 12 months was 88.0% (162/184). Four (2.0%) major adverse events occurred within 30 days. Twelve-month primary-assisted and secondary patency were 91.8% (169/184) and 92.9% (171/184), respectively. No stent fractures or migrations were reported. Mean target limb Villalta score decreased from 11.2±5.6 at baseline to 4.1±4.8 at 12 months, and the mean target limb revised Venous Clinical Severity Score decreased from 8.8±4.7 at baseline to 4.3±3.6 at 12 months. Clinically meaningful improvements in quality of life and venous functional assessment scores from baseline were demonstrated through 12 months in all measures. Conclusions: Symptomatic iliofemoral venous obstruction can be successfully treated with an Abre venous stent. Study outcomes demonstrated a high patency rate with a good safety profile. Patients demonstrated a significant reduction in clinical symptoms and improvement in quality of life that was maintained through 12-month follow-up. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03038438.

1 November 2018 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Closed access
SBStephen Black
Stephen Black
AGAdam Gwozdz
Adam Gwozdz
NKNarayan Karunanithy
Narayan Karunanithy
JSJustinas Silickas
Justinas Silickas
KBKaren Breen
Karen Breen
PSPrakash Saha
Prakash Saha

10 January 2022 in Journal of Vascular Surgery: Venous and Lymphatic Disorders
Verified
Journal Article
Closed access
MSMohamed Hosny Sayed
Mohamed Hosny Sayed
MSMurtaza Salem
Murtaza Salem
KDKush R. Desai
Kush R. Desai
GOGerard J. O'SUllivan
Gerard J. O'SUllivan
SBStephen A. Black
Stephen A. Black

23 February 2010 in British Journal of Surgery
Verified
Journal Article
Closed access
PDF file
SBS A Black
S A Black
DND. F. Nestel
D. F. Nestel
RKR. L. Kneebone
R. L. Kneebone
JWJ. H. N. Wolfe
J. H. N. Wolfe

1 October 2020 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Closed access
APAnna L. Pouncey
Anna L. Pouncey
AGAdam M. Gwozdz
Adam M. Gwozdz
OJOscar W. Johnson
Oscar W. Johnson
JSJustinas Silickas
Justinas Silickas
PSPrakash Saha
Prakash Saha
SBStephen A. Black
Stephen A. Black

21 October 2009 in British Journal of Surgery
Verified
Journal Article
Open access
PDF file
SBS A Black
S A Black
TCT W G Carrell
T W G Carrell
RBR E Bell
R E Bell
MWM Waltham
M Waltham
JRJ Reidy
J Reidy
PTP R Taylor
P R Taylor
Background: There is a common perception that a large number of secondary interventions are needed following endovascular aortic aneurysm repair. Methods: Prospective data were collected for a cohort of 417 consecutive elective patients undergoing infrarenal aortic endograft repair between April 2000 and May 2008. The rate of secondary interventions, associated morbidity and need for reintervention following surveillance imaging were analysed. Results: The male : female ratio was 11 : 1, median age 76 (range 40–93) years and median aneurysm diameter 6·1 (5·3–11) cm. The overall 30-day mortality rate was 1·7 per cent (seven of 417). Secondary interventions were performed in 31 patients (7·4 per cent), of which six (1·4 per cent) were detected by surveillance. Endoleaks requiring reintervention occurred in 12 patients (2·9 per cent; ten type I and two type III endoleaks). Limb ischaemia secondary to graft occlusion occurred in 17 patients (4·1 per cent); extra-anatomical bypass was needed in 15 patients (3·6 per cent) and the remaining two had an amputation. Graft explantation following late infection was required in two patients (0·5 per cent). Conclusion: Endoluminal repair of infrarenal aortic aneurysms can be performed with a low reintervention rate. The value of prolonged surveillance seems limited and current surveillance protocols may require revision.